DelveInsight’s “Dry AMD Market Insights, Epidemiology, and Market Forecast-2034” report delivers an in-depth understanding of the Dry AMD, historical and forecasted epidemiology as well as the Dry AMD market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Discover Key Insights into the Dry AMD Market with DelveInsight’s In-Depth Report @ Dry AMD Market Size
Key Takeaways from the Dry AMD Market Report
- In November 2024:- Stealth BioTherapeutics Inc.- A Phase 3, Double-Masked, Placebo-Controlled Clinical Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of Subcutaneous Injections of Elamipretide in Subjects Who Have Dry Age-Related Macular Degeneration (Dry AMD).
- In November 2024:- Cognition Therapeutics- This is a Phase 2, prospective, multicenter, randomized, double-masked, placebo-controlled 104-week study to assess the efficacy, safety, and tolerability of orally delivered CT1812 compared to placebo in participants with GA associated with dry AMD.
- The total prevalent cases of AMD in the 7MM was nearly 68,347,900 in 2023.
- Among the 7MM, the US accounted for the highest prevalent cases of dry AMD in 2023, with around 20,970,000 cases; these cases are expected to increase during the forecast period.
- Several researchers reported a declining prevalence of late AMD in the United States when comparing data from the 2000s with data gathered in previous decades.
- In 2023, the geographical atrophy accounted for nearly 955,900 cases in EU4 and the UK.
- According to the estimates, in Japan, it is observed that age-specific cases of geographic atrophy were most prevalent in the 85+ years age group, accounting for over 40% of total cases in 2023.
- The leading Dry Age-Related Macular Degeneration Companies such as Alkeus Pharmaceuticals, Novartis, Molecular Partners, Stealth BioTherapeutics, Regenerative Patch Technologies, Aevitas Therapeutics, NGM Biopharmaceuticals, InflammX Therapeutics, Lineage Cell Therapeutics, Alexion AstraZeneca Rare Disease, Belite Bio, Katairo, Cognition Therapeutics, Apellis Pharmaceuticals, Galimedix Therapeutics, Amarna Therapeutics, 4D Molecular Therapeutics, Aviceda Therapeutics, Isarna Therapeutics, and others.
- Promising Dry Age-Related Macular Degeneration Therapies such as Iptacopan (LNP023), ALK-001, RPESC-RPE-4W, PRIMA, QA102, Active Comparator CT1812, ASP7317, Tacrolimus, OCU410, GT005, AVD-104, and others.
Stay ahead in the Dry AMD Therapeutics Market with DelveInsight’s Strategic Report @ Dry AMD Market Outlook
Dry AMD Epidemiology Segmentation in the 7MM
- total prevalent cases of AMD,
- stage-specific prevalent cases of AMD,
- total prevalent cases of geographic atrophy,
- total prevalent cases of dry AMD,
- total diagnosed prevalent cases of dry AMD,
- age-specific cases of early and intermediate AMD,
- age-specific cases of geographic atrophy,
- geographic atrophy cases by visual impairment
Download the report to understand which factors are driving Dry AMD epidemiology trends @ Dry AMD Prevalence
Marketed Dry Age-related Macular Degeneration Drugs
IZERVAY (avacincaptad pegol): Astellas Pharma/Iveric Bio
IZERVAY, also known as avacincaptad pegol is designed to target and inhibit complement factor C5. Complement factor C5 is a central component of the complement cascade and is believed to be involved in the development and progression of dry AMD. IZERVAY binds to C5 and inhibits its cleavage into the terminal fragments C5a and C5b. By inhibiting the formation of complement system terminal fragments, IZERVAY may decrease the activation of inflammasomes and the formation of membrane attack complexes (MAC), which occur at the end of the complement cascade. In August 2023, the US FDA approved IZERVAY for the treatment of geographic atrophy secondary to AMD. Concurrently, Astellas Pharma announced that the European Medicines Agency (EMA) has accepted Iveric Bio’s MAA for avacincaptad pegol for the treatment of geographic atrophy secondary to AMD.
SYFOVRE (pegcetacoplan): Apellis Pharmaceuticals
SYFOVRE is a targeted C3 inhibitor designed to regulate excessive complement activation, which can lead to the onset and progression of many serious diseases. Pegcetacoplan is a type of synthetic cyclic peptide conjugated to a polyethylene glycol polymer that binds specifically to C3 and C3b. The company is evaluating pegcetacoplan in several clinical studies, including paroxysmal nocturnal hemoglobinuria (PNH), geographic atrophy (GA), cold agglutinin disease (CAD), warm antibody autoimmune hemolytic anemia (wAIHA), complement-dependent nephropathies (CDN). SYFOVRE is the first and only approved therapy for geographic atrophy secondary to AMD. In January 2024, the CHMP of the EMA adopted a negative opinion on the MAA of intravitreal pegcetacoplan for the treatment of geographic atrophy secondary to AMD.
Emerging Dry Age-related Macular Degeneration Drugs
- Iptacopan (LNP023): Novartis
Novartis Pharmaceuticals is developing Iptacopan, an oral small-molecule inhibitor of complement factor B (FB) with potential immunomodulatory activity. Upon administration, FB inhibitor LNP023 binds to FB and prevents the formation of the alternative pathway (AP) C3-convertase (C3bBb). This limits the cleavage of C3 to the active fragment C3b and may prevent C3b-mediated extravascular hemolysis in certain complement-driven disorders such as intermediate age-related macular degeneration (iAMD), C3 glomerulopathy (C3G), paroxysmal nocturnal hemoglobinuria (PNH), etc. Recently, in December 2023, the US FDA approved FABHALTA (ipatocan) as the first oral monotherapy for adults with paroxysmal nocturnal hemoglobinuria (PNH) (Novartis, 2023). Currently, the company is investigating iptacopan in the Phase II trial (NCT05230537) for the treatment of patients with early and intermediate age-related macular degeneration.
- ALK-001: Alkeus Pharmaceuticals
Allegro Ophthalmics is developing risuteganib (also known as ALG-1001), a breakthrough integrin-regulating therapy for ocular health that reduces mitochondrial dysfunction involved in intermediate dry AMD. By targeting multiple pathways, risuteganib helps reduce the cellular burden of oxidative stress and restores retinal homeostasis. Research suggests that risuteganib interferes with integrin functions that have been implicated in retinal diseases, giving it the potential for a broad-spectrum effect on different pathways of oxidative stress. Currently, the company has received the US FDA agreement under Special Protocol Assessment (SPA) for Phase IIb/III clinical trial of risuteganib for the treatment of intermediate, non-exudative age-related macular degeneration (dry AMD). Moreover, the overall protocol design of Phase IIb/III dry AMD clinical trial was finalized by the US FDA.
Get In-Depth Knowledge on Dry AMD Market Trends and Forecasts with DelveInsight @ Dry AMD Treatment Market
Dry AMD Market Outlook
Geographic atrophy, the advanced stage of dry AMD, has emerged as a prominent focus of research. Current investigations predominantly center on therapies targeting complement inhibitors of C3 and C5, pivotal factors in triggering inflammation and subsequent cell death within the eye. Extensive studies led by the National Eye Institute and esteemed researchers globally have unveiled the likelihood of an overactive complement system as a central player in the genesis of dry AMD and its evolution toward GA. Enhancing comprehension of the pathophysiology of geographic atrophy resulting from dry AMD can benefit patients, optometrists, and ophthalmologists alike. This improved understanding could lead to more accurate identification and diagnosis of patients, potentially lessening the burden of the disease and extending their visual function over time.
Dry AMD Drugs Market
Integrin inhibitor have been effective in several preclinical models, and promising results have been reported thus far from clinical trials. Indeed, most of the current avß3 clinical investigations centre on treating eye diseases (age-related macular degeneration (AMD) using topically dosed or intravitreally injected small molecules and peptides, although these molecules also inhibit other av integrins and/or a5ß1 to varying degrees. The molecules that have progressed the furthest in the clinic are risuteganib (Luminate, Allegro Ophthalmics). It is a small peptide integrin regulator protecting cells of the human RPE against dysfunction related to oxidative stress. With age, decreased mitochondrial oxidative phosphorylation increases the generation of reactive oxygen species and decreased metabolic activity, thus negatively affecting cellular bioenergetics and mitochondrial functioning. It is also known that RPE mitochondrial dysfunction contributes to the oxidative stress causing AMD.
Unlock Strategic Insights with DelveInsight’s Comprehensive Dry AMD Market Report @ Dry AMD Market Drivers and Barriers
Scope of the Dry AMD Market Report
- Coverage- 7MM
- Dry AMD Companies- Alkeus Pharmaceuticals, Novartis, Molecular Partners, Stealth BioTherapeutics, Regenerative Patch Technologies, Aevitas Therapeutics, NGM Biopharmaceuticals, InflammX Therapeutics, Lineage Cell Therapeutics, Alexion AstraZeneca Rare Disease, Belite Bio, Katairo, Cognition Therapeutics, Apellis Pharmaceuticals, Galimedix Therapeutics, Amarna Therapeutics, 4D Molecular Therapeutics, Aviceda Therapeutics, Isarna Therapeutics, and others.
- Dry Age-Related Macular Degeneration Therapies- Iptacopan (LNP023), ALK-001, RPESC-RPE-4W, PRIMA, QA102, Active Comparator CT1812, ASP7317, Tacrolimus, OCU410, GT005, AVD-104, and others.
- Dry AMD Therapeutic Assessment: Dry AMD Current marketed and Lipodystrophy Emerging Therapies
- Dry AMD Market Dynamics: Dry AMD Market drivers and Dry AMD Market Barriers
Table of Content
1. Key Insights
2. Executive Summary
3. Dry Age-Related Macular Degeneration Competitive Intelligence Analysis
4. Dry Age-Related Macular Degeneration Market Overview at a Glance
5. Dry Age-Related Macular Degeneration Disease Background and Overview
6. Dry Age-Related Macular Degeneration Patient Journey
7. Dry Age-Related Macular Degeneration Epidemiology and Patient Population
8. Dry Age-Related Macular Degeneration Treatment Algorithm, Current Treatment, and Medical Practices
9. Dry Age-Related Macular Degeneration Unmet Needs
10. Key Endpoints of Dry Age-Related Macular Degeneration Treatment
11. Dry Age-Related Macular Degeneration Marketed Products
12. Dry Age-Related Macular Degeneration Emerging Therapies
13. Dry Age-Related Macular Degeneration Seven Major Market Analysis
14. Attribute Analysis
15. Dry Age-Related Macular Degeneration Market Outlook (7 major markets)
16. Dry Age-Related Macular Degeneration Access and Reimbursement Overview
17. KOL Views on the Dry Age-Related Macular Degeneration Market
18. Dry Age-Related Macular Degeneration Market Drivers
19. Dry Age-Related Macular Degeneration Market Barriers
20. Appendix
21. DelveInsight Capabilities
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/case-study/in-licensing-opportunity